Related Experiment Video

Updated: Jun 22, 2026

Assaying the Kinase Activity of LRRK2 in vitro
06:09

Assaying the Kinase Activity of LRRK2 in vitro

Published on: January 18, 2012

Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions

Elisa Greggio1, Mark R Cookson

  • 1Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, 35 Convent Drive, Bethesda, MD 20982-3707, USA.

ASN Neuro
|July 3, 2009
PubMed

Insights

Mutations in leucine-rich repeat kinase 2 (LRRK2) are a common cause of inherited Parkinson's disease. This review explores LRRK2's normal function, how mutations impact it, and its role in neurotoxicity.

Area of Science:

  • Neuroscience
  • Genetics
  • Biochemistry

Background:

  • Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most frequent genetic cause of inherited Parkinson's disease.
  • LRRK2 is a large GTP-regulated serine/threonine kinase with multiple protein-protein interaction domains.

Purpose of the Study:

  • To address three key unresolved questions regarding LRRK2.
  • To investigate the normal function of LRRK2, including its GTPase and kinase activities, and protein interactions.
  • To examine the impact of mutations on LRRK2 function and explore LRRK2-mediated neurotoxicity mechanisms.

Main Methods:

  • Review of existing literature on LRRK2.
  • Analysis of in vitro data concerning LRRK2 kinase activity.
  • Discussion of LRRK2's known activities and their relation to neurotoxicity.

Main Results:

  • Evidence for LRRK2's GTPase and kinase activities is discussed.
  • Controversial findings regarding LRRK2 kinase activity in vitro are highlighted.
  • Potential mechanisms of LRRK2-mediated neurotoxicity are explored.

Conclusions:

  • Understanding LRRK2's normal function is crucial for deciphering its role in Parkinson's disease.
  • Further research is needed to resolve controversies surrounding LRRK2 mutations and kinase activity.
  • Elucidating LRRK2's neurotoxic pathways may offer therapeutic targets for Parkinson's disease.

More Related Videos

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate11:31

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate

Published on: September 18, 2013

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag08:55

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag

Published on: December 14, 2017

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...